Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pentavalent rotavirus vaccine
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Pentavalent rotavirus vaccine is a live attenuated oral biologic designed to prevent rotavirus infection, a leading cause of severe gastroenteritis in infants and young children. The vaccine typically contains five live reassortant rotavirus strains targeting multiple serotypes (such as G1, G2, G3, G4, and P[8] or G9). One specific formulation, **Rota-V-Aid™**, was developed by **Pharm Aid** in collaboration with the **Serum Institute of India** as a freeze-dried (lyophilized) oral preparation. It functions by stimulating a mucosal and systemic immune response against the rotavirus pathogen. Clinical evaluations, including Phase 3 trials in healthy infants, have demonstrated its efficacy and safety in preventing rotavirus-related gastroenteritis.
- Brand names
- Rota-V-AidRotaTeqROTASIIL
- Other names
- pentavalent live attenuated rotavirus vaccineRV5RV-5RV 5rotavirus vaccine, live attenuated, bovine-human reassortant, pentavalent
02
Targets
RVA (Rotavirus A)
Beyond the preview
Go deeper on pentavalent rotavirus vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pentavalent rotavirus vaccine.